Non-Executive Chairman and Chairman of Nomination Committee
Current roles: John Clarke became Chairman of Futura Medical plc in 2012. He is a member of the Nominations Committee and the Remuneration Committee. He is also the Non-Executive Chairman of Science in Sport plc and Kind Consumer Holdings Limited and a senior advisor to Helios Investment Partners LLP.
Past roles: Appointed President of GSK Consumer Healthcare in 2006, a position from which he stepped down in 2011. Under his leadership, GSK Consumer Healthcare became one of the fastest-growing companies in its industry. Non-executive Chairman of Quantum Pharma Plc.
Brings to the Board: Extensive experience of the healthcare sector, having worked at GSK for more than 35 years.
Current roles: James Barder joined the Group as Chief Executive in 2001. He assists the Remuneration Committee and the Nominations Committee (but is not a member of and does not vote on either). He has overall responsibility for all activities of the Group, is a principal contact for shareholder and investor relations matters and leads commercial negotiations. He first became involved with the Group in 1997.
Past roles: Managing Director of Aon Capital Markets Limited and Non-Executive Director of Lorega Limited. James has predominantly worked in the field of insurance and finance including firms he founded.
Brings to the Board: Over 25 years of experience in setting up, managing and running companies.
Finance Director and Chief Operating Officer
Current roles: Angela joined the company in February 2018. She leads the Group's finance, HR and IT functions, inputs into commercial and financial strategy, ensures its compliance procedures and is a principal contact for shareholder and investor relations matters.
Past roles: Senior financial roles in a diverse range of industries, including the past 7 years as UK Finance Director at Shield Therapeutics Plc (listed on AIM stock exchange).
Brings to the Board: Strategic and operational financial experience of developing and commercialising pharmaceutical products.
Executive Director and Head of R&D
Current roles: Ken James joined the Board in April 2016. In November 2016 he was appointed Head of R&D. He oversees the development, regulatory and manufacturing strategies for the company's existing pipeline and the evaluation of early stage pipeline opportunities. He is a member of the Nominations Committee, the Remuneration Committee and the Audit Committee.
Past roles: Senior Vice President of Research and Development for GlaxoSmithKline Worldwide Consumer Healthcare, having worked in the UK and the United States.
Brings to the Board: Over 40 years' experience in the research, development and commercialisation of consumer healthcare products.
Jonathan Freeman, BA (Hons), MBA
Senior Independent Non-Executive Director and
Chairman of Remuneration Committee and Audit Committee
Current roles: Jonathan Freeman joined the Board in 2003 and was appointed Senior Independent Non-Executive Director in November 2003. He chairs the Audit Committee and the Remuneration Committee and is also a member of the Nominations Committee. He is also an Executive Director of Braveheart Investment Group plc and a Director of PhotonStar LED Group plc.
Past roles: Director of Beeson Gregory, Chief Executive Officer of Syndicate Asset Management plc and a Director of Hume Securities plc.
Brings to the Board: Over 25 years of experience in the financial services sector, guidance on City regulatory matters, corporate finance and investor relations.
Page last updated: 14 March 2018
You may also be interested in: